Biotech Stocks Surging in September

CORAL GABLES, FL / ACCESSWIRE / September 18, 2017 / Biotech Stocks are back on a bullish sentiment after two key announcements that led to rally in the sector. The first key announcement was Gildead Sciences announcing it will acquire immunotherapy company, Kite Pharma for nearly $12 billion. The second announcement was the FDA approving the first gene therapy in the United States, developed by Novartis AG’s Kymriah, which drove the sector higher.

The Gilead-Kite deal increased expectations that the Biotech sector will begin to see more M&A deals in future quarters, and companies that include CAR-T treatments like Kite pharma saw a hike in their stock price on hopes that we will see more M&A deals in this section of the Biotech market.

To date, the Nasdaq Biotechnology Index has gained 26.1% signifying a strong rally to the index’s performance during the same time last year when it posted a decline of 18.2%. With that being said, a number of biotech companies have created a buzz in the market over the last couple of weeks.

GT Biopharma (OXISD) an immuno-oncology company focused on developing drugs that treat cancer has made several key announcements as of late. The company recently announced the completion of its M&A of Georgetown Translational Pharmaceuticals, Inc. The company also announced on 9/11, that they now have the ability to license and develop PainBrake, a non-opioid pain medication.

Another key highlight to mention is the appointment of their new Chief Medical Officer Dr. Raymond Ubanksi. Dr Ubanksi brings years of experience in the biotech industry to the (OXISD) team, including servicing as Chief Medical Officer for Mylan Inc. and Vice President/CMO of the Established Products Business Unit at Pfizer. To access a full report on GT Biopharma (OXISD) Click Here.

Plurstem Therapeutics Inc. (NASDAQ: PSTI) a leading developer of placenta-based cell therapy products saw a hike of 19.40% in price per share during Monday morning’s trading session from Friday’s (9/15) close. The spike came of the heels of an announcement on pre-market Monday, announcing the company has been granted fast track designation from the FDA for their ongoing Phase III study of PLX-PAD cells.

“We are extremely pleased with the FDA’s decision to grant Fast Track Designation to PLX-PAD in the treatment of CLI. Up to 40% of patients with CLI are ineligible for revascularization and are at high risk of amputation and death within the first year of diagnosis. This disease takes a heavy toll on patients and their families, while the cost of treating CLI in the U.S. alone is estimated at over $25 billion per year. We are working tirelessly to provide a cell therapy that will address this severe unmet medical need,” stated Zami Aberman, Chairman and Co-CEO of Pluristem.

BIOTECHSTOCKS

About BiotechStocks.com

BIOTECHSTOCKS,.com is owned by MIDAM VENTURES LLC., a Florida Corporation that has been compensated $550,000.00 by a GT Biopharma Inc. for a period beginning August 1, 2017 and ending Oct. 1, 2017 now extended to October 1, 2017 to publicly disseminate information about (OXISD). We own zero shares. MIDAM Ventures has previously been compensated eleven thousand shares of Plurstem Therapeutics Inc. Full Disclaimer Here.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither BTS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://biotechstocks.com.

NO WARRANTY

BTS, the Author and the Reviewer (collectively referred to as the “Publishers”) are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by the Publishers whatsoever for any direct, indirect or consequential loss arising from the use of this document. The Publishers expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise, arising from any reliance placed on the information in this document. Additionally, the Publishers do not (1) guarantee the accuracy, timeliness, completeness, or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

Contact:

news@biotechstocks.com

SOURCE: BiotechStocks.com

ReleaseID: 475663